Cite
HARVARD Citation
De Bono, J. et al. (n.d.). 2560 Baseline serum clusterin level in patients with poor prognostic features was associated with response to custirsen treatment: Results from the phase 3 SYNERGY trial of docetaxel +/- custirsen. European journal of cancer. pp. S497-. [Online].